MAIA touts $50B immunotherapy market; ateganosine gets Fast Track for NSCLC, Phase 3 starting

MAIA Biotechnology, Inc.

FDA Fast Track Designation for ateganosine in NSCLC patients resistant to immunotherapy and chemotherapy.
Initiating Phase 3 THIO-104 trial for advanced NSCLC without actionable mutations and CPI-refractory.
FDA Orphan Drug Designations for glioblastoma, hepatocellular carcinoma, and small cell lung cancer.
NSCLC market valued at $34.1B, projected to nearly double to $68.8B by 2033.
Keytruda generated $29.5B revenue in 2024, with ~30% from NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.